Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalMEX:BMRN 80 PE Ratio (TTM) is 37.32 as of Jul. 14, 2026, which is 45% below its 10-year median of 68.13. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,506.12 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 271 Biotechnology companies, BioMarin Pharmaceutical ranks worse than 69.74% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-14), BioMarin Pharmaceutical's share price is
MXN959.00.
BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN25.70. Therefore, BioMarin Pharmaceutical's PE Ratio (TTM) for today is 37.32.
Warning Sign:
BioMarin Pharmaceutical Inc stock PE Ratio (=43.21) is close to 1-year high of 43.21.
The historical rank and industry rank for BioMarin Pharmaceutical's PE Ratio (TTM) or its related term are showing as below:
MEX:BMRN'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 15.98 Med: 68.13 Max: 1143.38
Current: 43.21
During the past 13 years, the highest PE Ratio (TTM) of BioMarin Pharmaceutical was 1143.38. The lowest was 15.98. And the median was 68.13.
MEX:BMRN's PE Ratio (TTM) is ranked worse than 69.74% of 271
companies
in the Biotechnology industry
Industry Median: 27.87
vs MEX:BMRN: 43.21
During the past 13 years, BioMarin Pharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 138.90% per year. The lowest was -82.80% per year. And the median was 2.35% per year.
BioMarin Pharmaceutical (MEX:BMRN) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
BioMarin Pharmaceutical PE Ratio (TTM) Related Terms
BioMarin Pharmaceutical PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's PE Ratio (TTM) falls into.
BioMarin Pharmaceutical PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
BioMarin Pharmaceutical's Share Price of today is MXN959.00.
BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN25.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
BioMarin Pharmaceutical (MEX:BMRN) has a PE Ratio (TTM) of 37.32 as of Jul. 14, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on BioMarin Pharmaceutical and its competitors. This is 45% below median its historical median of 68.13. Over the past decade, BioMarin Pharmaceutical's PE Ratio (TTM) has ranged from 15.98 to 1,143.38. According to the industry distribution chart, BioMarin Pharmaceutical ranks #189 out of 271 companies in the Biotechnology industry, placing it in the top 69.7%.
Is BioMarin Pharmaceutical's PE Ratio (TTM) too high?
BioMarin Pharmaceutical's current PE Ratio (TTM) of 37.32 is 45% below median its 10-year median of 68.13. Over the past 10 years, this metric has ranged from a low of 15.98 to a high of 1,143.38. The Biotechnology industry median PE Ratio (TTM) is 27.87. BioMarin Pharmaceutical's value of 37.32 is 33.9% above this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #189 out of 271 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's PE Ratio (TTM) compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #189 out of 271 companies for PE Ratio (TTM). This places BioMarin Pharmaceutical in the lower half of its industry. The industry median PE Ratio (TTM) is 27.87. BioMarin Pharmaceutical's value of 37.32 is 33.9% above this benchmark. Historically, BioMarin Pharmaceutical's own PE Ratio (TTM) has ranged from 15.98 to 1,143.38 over the past decade. While the company's 10-year median is 68.13 vs. the industry median of 27.87, BioMarin Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.87, based on 271 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current PE Ratio (TTM) of 37.32 is 33.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current PE Ratio (TTM) is 37.32, which is 45% below median its own 10-year median of 68.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,506.12, compared to a current price of MXN959.00 — trading 36.3% below its estimated fair value. The current PE Ratio (TTM) is 37.32, which is 45% below median its 10-year median of 68.13 and 33.9% above the Biotechnology industry median of 27.87. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current PE Ratio (TTM) is 37.32 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.3% below its estimated GF Value™ of MXN1,506.12.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
PE Ratio (TTM): 37.32 (45% below median its 10-year median of 68.13)
GF Value™: MXN1,506.12 vs. price of MXN959.00 (36.3% below fair value)
Industry Position: 33.9% above the Biotechnology median (#189 of 271)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
